Onkologie. 2012:6(5):269-271

Neoadjuvant chemotherapy in livermetastatic colorectal carcinoma

Miroslav Ryska
Chirurgická klinika 2. LF UK a ÚVN, Praha

The occurrence of livermetastatic colorectal carcinoma is related to the incidence of colorectal cancer (CRC) which, in the Czech Republic,

is one of the highest worldwide with approximately 90 new cases per 100.000 inhabitants/year. Overall, 9.000 new cases of the disease

occur annually. Sixty percent of them develop generalized disease in the form of liver metastases. Radical treatment involves liver resection

and administration of adjuvant chemotherapy. The authors report the types of liver resections, the degree of radicality, the factors

resulting in contraindication of liver resection as well as the options of increasing the percentage of resectability. The best treatment

outcomes are achieved with a multimodal approach using a personalized approach to each patient.

Keywords: colorectal cancer, liver metastases, liver resection, chemotherapy, multimodal approach

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryska M. Neoadjuvant chemotherapy in livermetastatic colorectal carcinoma. Onkologie. 2012;6(5):269-271.
Download citation

References

  1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683. Go to original source... Go to PubMed...
  2. Liévre A, Bachet JB, Bojte V, et al. KRAS mutation as an independent prognostic factor in patiens with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379. Go to original source... Go to PubMed...
  3. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resectio/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825. Go to original source... Go to PubMed...
  4. de Haas RJ, Wicherts DA, Salloum C, et al. Long-term outcomes after hepatic resection for colorectal metastases in young patiens. Cancer 2010; 116: 647-658. Go to original source... Go to PubMed...
  5. Ryska M, Barkmannová J, Pudil J, et al. Multidisciplinární tým v léčbě kolorektálního karcinomu. Praktické zkušenosti, příklad spolupráce VFN a ÚVN. Colorectal News 2012; 1: 15-17.
  6. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016. Go to original source... Go to PubMed...
  7. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010; 252: 774-787. Go to original source... Go to PubMed...
  8. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658. Go to original source... Go to PubMed...
  9. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249. Go to original source... Go to PubMed...
  10. Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patiens with unresectable colorectal liver metastases: A multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 2005; 22: 303-312. Go to original source... Go to PubMed...
  11. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939. Go to original source... Go to PubMed...
  12. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 1061-1064. Go to original source... Go to PubMed...
  13. LiverMetSurvey. International Registry of Patiens Operated for Colorectal Liver Metastasis. Available at http://www.livermetsurvey.org, accessed November 23, 2011.
  14. Bouchahda M, Adam R, Giacchetti S, et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009; 115: 4990-4999. Go to original source... Go to PubMed...
  15. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671. Go to original source... Go to PubMed...
  16. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47. Go to original source... Go to PubMed...
  17. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1542-1547. Go to original source... Go to PubMed...
  18. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5 fluorouracil/foliante/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011; 29 (Suppl. 4): 365. Go to original source...
  19. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697-4705. Go to original source... Go to PubMed...
  20. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17: 2870-2876. Go to original source... Go to PubMed...
  21. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048. Go to original source... Go to PubMed...
  22. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The Oncologist 2012 September (Epub ahead of print). Go to original source... Go to PubMed...
  23. Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decision - making on treatment strategie for colorectal liver metastases. Br J Surg 2012; 99: 163-1269. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.